Viloksazinas

Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) that also modulates serotonergic activity as a 5-HT2B antagonist and 5-HT2C agonist. Originally used as an antidepressant in Europe (1974-2002), it was repurposed and FDA-approved in 2021 for ADHD treatment in the US under the brand name Qelbree. It is generally well-tolerated but may cause insomnia, irritability, somnolence, or gastrointestinal upset. Higher rates of suicidal thoughts and behaviors have been reported in pediatric patients, requiring close monitoring especially during initial treatment. Caution is advised in patients with liver or severe renal impairment, bipolar disorder, or those taking CYP1A2 substrates.

Also known as: Emovit, Qelbree, Vivalan, Vicilan, Vivarint

Classification

Psychoactive: Nootropic
Psychoactive: Stimulant
Tag: ADHD treatment
Tag: Antidepressant
Tag: Morpholine derivative
Tag: Tentative

Effects

Mild Stimulation
Somnolence
Insomnia
Headache
Decreased Appetite
Nausea
Improved Attention
Reduced Hyperactivity
Reduced Impulsivity
Increased Focus
Irritability
Cognitive Euphoria
Light Sensitivity
Disinhibition
Tactile Suppression
Hallucinations
Visual Disconnection
Double Vision

Routes of Administration

Oral

Dosage

Common: 75-150 mg
Light: 50-75 mg
Strong: 150 mg

Duration

Onset: 2 h
Comeup: 2-4 h
Peak: 5 h
Offset: 12-18 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu